Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/36154
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | BAETEN, Paulien | - |
dc.contributor.author | VAN ZEEBROECK, Lauren | - |
dc.contributor.author | KLEINEWIETFELD, Markus | - |
dc.contributor.author | HELLINGS, Niels | - |
dc.contributor.author | BROUX, Bieke | - |
dc.date.accessioned | 2021-12-13T12:50:50Z | - |
dc.date.available | 2021-12-13T12:50:50Z | - |
dc.date.issued | 2022 | - |
dc.date.submitted | 2021-08-27T13:03:36Z | - |
dc.identifier.citation | CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY, 62 (2) ,p. 363-381 | - |
dc.identifier.uri | http://hdl.handle.net/1942/36154 | - |
dc.description.abstract | Autoimmunity is caused by an unbalanced immune system, giving rise to a variety of organ-specific to system disorders. Patients with autoimmune diseases are commonly treated with broad-acting immunomodulatory drugs, with the risk of severe side effects. Regulatory T cells (Tregs) have the inherent capacity to induce peripheral tolerance as well as tissue regeneration and are therefore a prime candidate to use as cell therapy in patients with autoimmune disorders. (Pre)clinical studies using Treg therapy have already established safety and feasibility, and some show clinical benefits. However, Tregs are known to be functionally impaired in autoimmune diseases. Therefore, ex vivo manipulation to boost and stably maintain their suppressive function is necessary when considering autologous transplantation. Similar to autoimmunity, severe coronavirus disease 2019 (COVID-19) is characterized by an exaggerated immune reaction and altered Treg responses. In light of this, Treg-based therapies are currently under investigation to treat severe COVID-19. This review provides a detailed overview of the current progress and clinical challenges of Treg therapy for autoimmune and hyperinflammatory diseases, with a focus on recent successes of ex vivo Treg manipulation. | - |
dc.description.sponsorship | The authors are funded by Fonds voor Wetenschappelijk Onderzoek (FWO), the Belgian Charcot Stichting, Stichting MS Research, MS International Foundation, and MoveS. | - |
dc.language.iso | en | - |
dc.publisher | HUMANA PRESS INC | - |
dc.rights | The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2021 | - |
dc.subject.other | Regulatory T cells | - |
dc.subject.other | Cell therapy | - |
dc.subject.other | Autoimmunity | - |
dc.subject.other | COVID-19 | - |
dc.subject.other | Gene editing | - |
dc.subject.other | RNA interference | - |
dc.title | Improving the Efficacy of Regulatory T Cell Therapy | - |
dc.type | Journal Contribution | - |
dc.identifier.epage | 381 | - |
dc.identifier.issue | 2 | - |
dc.identifier.spage | 363 | - |
dc.identifier.volume | 62 | - |
local.bibliographicCitation.jcat | A1 | - |
local.publisher.place | 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA | - |
local.type.refereed | Refereed | - |
local.type.specified | Review | - |
dc.identifier.doi | 10.1007/s12016-021-08866-1 | - |
dc.identifier.pmid | 34224053 | - |
dc.identifier.isi | 000669750200001 | - |
local.provider.type | Web of Science | - |
local.uhasselt.international | yes | - |
item.contributor | BAETEN, Paulien | - |
item.contributor | VAN ZEEBROECK, Lauren | - |
item.contributor | KLEINEWIETFELD, Markus | - |
item.contributor | HELLINGS, Niels | - |
item.contributor | BROUX, Bieke | - |
item.fullcitation | BAETEN, Paulien; VAN ZEEBROECK, Lauren; KLEINEWIETFELD, Markus; HELLINGS, Niels & BROUX, Bieke (2022) Improving the Efficacy of Regulatory T Cell Therapy. In: CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY, 62 (2) ,p. 363-381. | - |
item.accessRights | Open Access | - |
item.fulltext | With Fulltext | - |
item.validation | ecoom 2022 | - |
crisitem.journal.issn | 1080-0549 | - |
crisitem.journal.eissn | 1559-0267 | - |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Baeten et al 2021 Improving the efficacy of regulatory T cell therapy.pdf | Peer-reviewed author version | 1.34 MB | Adobe PDF | View/Open |
s12016-021-08866-1.pdf Restricted Access | Published version | 1.16 MB | Adobe PDF | View/Open Request a copy |
WEB OF SCIENCETM
Citations
20
checked on Apr 30, 2024
Page view(s)
40
checked on Jul 5, 2022
Download(s)
8
checked on Jul 5, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.